Fed Circuit limits venue options for generic patent suits

The US Court of Appeals for the Federal Circuit has narrowed the landscape in which patent infringement suits over generic drugs suits can be filed, in a ruling handed down yesterday, November 5.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circuit affirms generic maker’s win over Eagle

11 May 2020 The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

Americas

Teva and Mylan implore Fed Circuit not to stay immunity ruling

7 November 2018 Generic makers Teva, Mylan and Akorn asked the US Court of Appeals for the Federal Circuit not to stay to its sovereign immunity ruling pending an appeal by Allergan and the Saint Regis Mohawk Tribe to the US Supreme Court.

More on this story

Americas

Fed Circuit affirms generic maker’s win over Eagle

11 May 2020 The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

Americas

Teva and Mylan implore Fed Circuit not to stay immunity ruling

More on this story

Americas

Fed Circuit affirms generic maker’s win over Eagle

11 May 2020 The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

Americas

Teva and Mylan implore Fed Circuit not to stay immunity ruling